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ABSTRACT 
Background: People with MS (pwMS) have had higher rates of anxiety and depression than the 
general population before the COVID-19 pandemic, placing them at higher risk of experiencing poor 
psychological wellbeing during the pandemic. 
Objective: To assess mental health and its social/lifestyle determinants in pwMS during the first 
wave of the outbreak in the UK 
Methods: This is a community-based, prospective longitudinal cohort and cross-sectional case-
control online questionnaire study. It includes 2,010 pwMS from the UK MS Register and 380 people 
without MS. 
Results: The Hospital Anxiety and Depression Scale scores of pwMS for anxiety and depression 
during the outbreak did not change from the previous year. PwMS were more likely to have anxiety 
(using General Anxiety Disorder-7) and/or depression (using Patient Health Questionnaire-9) than 
controls during the outbreak (OR:2.14[95%CI:1.58-2.91]). PwMS felt lonelier (OR:1.37[95%CI:1.04-
1.80]), reported worse social support (OR:1.90[95%CI:1.18-3.07]) and reported worsened exercise 
habits (OR:1.65[95%CI:1.18-2.32]) during the outbreak than controls. 
Conclusion: Early in the pandemic, pwMS remained at higher risk of experiencing anxiety and 
depression than the general population. It is important that multidisciplinary teams improve their 
support for the wellbeing of pwMS, who are vulnerable to the negative effects of the pandemic on 
their lifestyle and social support.  
INTRODUCTION 
The coronavirus disease-2019 (COVID-19) pandemic transformed the lives of people in unpredictable 
ways and posed a risk to their mental wellbeing.1 Early in the pandemic, the United Kingdom (UK) 
general population experienced higher levels of psychological distress compared to the pre-COVID-
19 era.2 Consequently, research on mental health effects of the pandemic across vulnerable groups 
became a multidisciplinary research priority.3 
At the start of the outbreak, anecdotal evidence suggested considerable fear of COVID-19 amongst 
people with multiple sclerosis (pwMS) because of their long-term physical disabilities and the 
immunosuppression caused by some disease modifying therapies (DMTs). The assessment of anxiety 
and depression in pwMS was specifically warranted because pwMS were known to have higher pre-
COVID-19 rates of anxiety and depression than the general population.4, 5 Furthermore, similar to the 
general population, changes in lifestyle and social factors could influence the mental health of pwMS. 
5-8 
Therefore, we aimed to assess: 
(i) mental health, its lifestyle and social determinants, and its association with general health among 
pwMS during the outbreak and compare them to people without MS. 
(ii) levels of anxiety and depression amongst pwMS before and after the outbreak. 
PATIENTS AND METHODS 
Study design, setting and participants 
The MS-COVID-19 study is an ongoing community-based, prospective and longitudinal cohort study 
conducted as part of the UK MS Register (UKMSR) (clinicaltrials.gov: NCT04354519).9 The 
UKMSR has been collecting patient-reported data from pwMS since 2011.10 For the MS-COVID-19 
study, we have been collecting COVID-19 related data from pwMS using online self-administered 
questionnaires since 17 March 2020- the beginning of the COVID-19 outbreak in the UK. 
On 22 May 2020, we invited pwMS registered with the UKMSR (including pwMS who were taking 
part in the MS-COVID-19 study) by email to complete questionnaires about their mental health, its 
social and lifestyle determinants, and their general health on a one-off basis (Supplementary 
Material). In addition, we provided them with a link to invite people without MS (“controls”) to 
complete these same questionnaires, adding a case-control component to the study. PwMS and 
controls who responded to at least one of the questionnaires were included in the study (i.e., 
participants of the mental health study). The study flow diagram is depicted in Figure 1. 
In this paper, we report cross-sectional findings on the mental health of pwMS, its determinants, and 
their general health during the outbreak (22 May 2020 to 16 July 2020) and compare them to controls. 
We also report longitudinal findings on anxiety and depression levels of pwMS pre-COVID-19 (28 
February to 01 April 2019 and 3 September to 1 October 2019) and post-COVID-19 (7 February to 12 
May 2020). We report the study according to the STROBE guidelines. 
Ethical approval and consent 
Ethical approval for UKMSR studies was obtained from South West-Central Bristol Research Ethics 
Committee (16/SW/0194). The case-control study received separate ethical approval from the 
Departmental Ethics Committee (4913-4902). Participants provided informed consent online. 
Data collection 
The UKMSR data 
The UKMSR holds demographic data (age, gender, ethnicity), clinical data (type of MS, MS disease 
duration from diagnosis, DMTs), web-based Expanded Disability Status Scale (webEDSS) scores,11 
and Hospital Anxiety and Depression Scale scores of registered pwMS.12 We used the last webEDSS 
scores collected from 9 February 2017 to 3 August 2020 to measure physical disability in pwMS. We 
used HADS scores for anxiety (HADS-A) and depression (HADS-D) among pwMS to compare their 
anxiety and depression levels during the outbreak to the year before. We considered a HADS score 
≥11 as probable caseness of anxiety or depression (referred to as having HADS-anxiety or HADS-
depression, here).13 HADS scores for controls were not available. 
The MS-COVID-19 study data 
In the MS-COVID-19 study, we asked pwMS whether they were self-isolating and whether they had 
symptoms suggestive of a diagnosis of COVID-19.9 These data were not available for controls. 
Mental health questionnaires 
We used the General Anxiety Disorder 7-item (GAD-7) and Patient Health Questionnaire 9-question 
(PHQ-9) scales to assess anxiety and depression, respectively, among pwMS and controls during the 
outbreak.14, 15 We used a cut-off ≥10 for probable caseness of anxiety or depression (referred to as 
having anxiety or depression, here).13 
We used the Impact of Event Scale-Revised (IES-R) to assess symptoms of post-traumatic stress 
disorder (PTSD) in pwMS and controls during the outbreak.16 We considered scores ≥33 as probable 
caseness of PTSD (referred to as having PTSD, here).16 We considered the IES-R subscales, including 
avoidance, hyperarousal, and intrusion in the analysis.16 
To measure optimism during the outbreak, we used the Revised Life Orientation Test (LOT-R) scale 
with higher scores indicating more optimism.17 
Social and lifestyle determinants of mental health questionnaires 
We developed a questionnaire to assess whether participants had any changes (better/worse) in their 
lives related to social (relationships, social support, work, feeling of loneliness) and lifestyle (exercise, 
diet, smoking, and alcohol intake) factors during the outbreak compared to the year before. 
Participants used a visual analogue scale to indicate the change, with “no change” in the middle (45-
55), “better” to the right (56-100), and “worse” to the left (0-44). 
General health and MS symptoms questionnaires 
We asked participants to report how their general health and (only for pwMS) MS symptoms had 
changed during the outbreak compared to the year before. We developed a similar questionnaire as 
described above. 
Statistical analysis 
Data were analysed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, N.Y., 
USA; 2017) and R (R Core Team, 2019). 
Cross-sectional analysis 
Continuous variables were assessed for normality of distribution by visual inspection of data. Data 
were analysed using the Mann-Whitney U test and presented as median (interquartile range [IQR]) 
when not normally distributed and using the t-test and presented as mean (standard deviation [SD]) 
when normally distributed. The Mann-Whitney U test was also used for assessing ordinal variables. 
To assess the association between categorical variables, the Chi-square test was used (Fischer’s exact 
test when expected count ≤5). 
For comparisons between pwMS and controls, multivariable logistic regression analysis was used- 
binomial or multinomial, based on the dependent variable. To ascertain the association between 
mental health variables or having had COVID-19 and changes in general health or MS symptoms, 
multivariable multinomial logistic regression analysis was used. In each regression analysis, no 
change in the outcome was set as the reference value. 
Directed Acyclic Graphs (DAGs) were built to determine potential confounding factors for individual 
regression analyses (Supplementary Material).18 A separate DAG was used for each exposure and 
outcome analysis model.18 We chose this approach to avoid introducing bias by controlling for 
colliders and mediators in the regression analyses models which is a common issue in psychological 
research.19 Confounding factors controlled for in each analysis have been stated in the results, and 
where not mentioned, adjustments for age, gender, and ethnicity were made. Listwise deletion was 
implemented for missing data. The number of cases included in each regression analysis has been 
indicated where there was missing data. The results of the regression analyses are presented as odds 
ratio (OR) and 95% confidence intervals (95%CI). 
Longitudinal analysis 
The HADS scores of pwMS before and during the outbreak were compared using the Mann Whitney 
U test (paired). The proportion of pwMS with HADS-anxiety or HADS-depression before and during 
the outbreak were compared using the McNemar’s test. 
RESULTS 
Participants 
A total of 2,010 pwMS and 380 controls were included in the study (Figure 1). Characteristics of 
pwMS (participants and non-participants from the total UKMSR population) and controls are 
presented in Table 1. A total of 2,226 pwMS on the UKMSR had provided a HADS score both during 
and before the outbreak (1,165 were participants of the mental health study). 
Anxiety, depression, and PTSD 
Mental health characteristics of pwMS and controls are presented in Table 2. 
PwMS were more likely to have anxiety and/or depression during the outbreak than controls 
(n=1,982; OR 2.14, 95%CI 1.57-2.91). The likelihood of having PTSD in pwMS during the outbreak 
was not different from controls (n=1,996; OR 1.13, 95%CI 0.84-1.52). 
The HADS scores of pwMS during the outbreak had not significantly changed from their last score 
the year before (Table 3). 
Having had COVID-19 was not associated with having anxiety and/or depression during the outbreak 
(after the infection, if present) (OR 1.43, 95%CI 0.75-2.74) (n=1,128; adjusted for age, gender, 
ethnicity, webEDSS, self-isolation, taking DMTs, and HADS-anxiety and/or HADS-depression 
before the outbreak). HADS-anxiety and/or HADS-depression before the outbreak did not predict 
self-reporting COVID-19 among pwMS (OR 1.04, 95%CI 0.73-1.48) (n=2,655; adjusted for age, 
gender, webEDSS, and taking DMTs). 
General health and MS symptoms 
A total of 1,829 pwMS and 274 controls responded to the change in general health question, and 
1,829 pwMS responded to the change in MS symptoms question (Table 4). 
PwMS were more likely than controls to report a decline in their general health during the outbreak 
compared to before (OR 1.95, 95%CI 1.43-2.65). In a post hoc analysis, we compared this outcome 
(decline in general health) between pwMS and controls separately within two groups: 1) participants 
with anxiety and/or depression, and 2) participants without anxiety or depression. Among participants 
without anxiety or depression (n=1,263), the findings were similar: pwMS had a higher likelihood of a 
decline in general health than controls (OR 1.79, 95%CI 1.16-2.76). However, among participants 
with anxiety or depression (n=673), there was no difference between pwMS and controls in reporting 
a decline in general health (OR 1.51, 95%CI 0.86-2.65). 
Among only pwMS, the general health of participants with anxiety and/or depression during the 
outbreak was more likely to deteriorate than those without anxiety or depression (OR 3.59, 95%CI 
2.71-4.76) (n=1,398; adjusted for age, webEDSS, self-diagnosed COVID-19, LOT-R, and changes in 
loneliness). 
PwMS with COVID-19 were more likely to report deterioration in their general health than those 
without COVID-19 (OR 1.99, 95%CI 1.07-3.69) (n=1,055; adjusted for age, gender, ethnicity, 
webEDSS, taking DMTs, self-isolation, and changes in HADS-A and HADS-D from before the 
outbreak). 
PwMS with anxiety and/or depression during the outbreak were more likely to report worsening of 
their MS symptoms compared to those without anxiety or depression (OR 5.23, 95%CI 4.16-6.57) 
(n=1,611; adjusted for taking DMTs, MS type, COVID-19, and LOT-R). 
Having had COVID-19 predicted a higher likelihood of MS symptoms worsening (OR 1.97, 95%CI 
1.06-3.67) (n=1,052; adjusted for age, gender, ethnicity, webEDSS, taking DMTs, self-isolation, and 
changes in HADS-A and HADS-D from before the outbreak). 
Social and lifestyle determinants of mental health during the outbreak 
Changes in social and lifestyle factors of pwMS and controls during the outbreak are presented in 
Table 5. 
PwMS were more likely to feel lonelier than controls (OR 1.36, 95%CI 1.04-1.80). Among pwMS 
with anxiety and/or depression during the outbreak, 73.3% (n=442) reported feeling lonelier as 
opposed to 31.5% (n=340) of those without anxiety or depression (p<0.001). The findings were 
similar among pwMS with and without HADS-anxiety and/or HADS-depression before the outbreak 
(60.5% [n=214] vs 37.2% [n=336] felt lonelier, p<0.001). 
PwMS were more likely to experience worsening of their social support than controls (OR 1.90, 
95%CI 1.18-3.07). A larger proportion of pwMS with anxiety and/or depression during the outbreak 
reported worsening of their social support than those without anxiety or depression (23.9% [n=144] vs 
9.5% [n=103], p<0.001)- similar to those with and without HADS-anxiety and/or HADS-depression 
before the outbreak (24% [n=85] vs 11% [n=99], p<0.001). The likelihood of experiencing worse 
relationships during the outbreak among pwMS was not significantly different from controls (OR 
1.35, 95%CI 0.93-1.96), but pwMS were less likely to report having better relationships compared to 
before the outbreak (OR 0.65, 95%CI 0.48-0.88). 
The exercise habits of pwMS were more likely to become worse than controls (OR 1.65, 95%CI 1.18-
2.32). Among pwMS, HADS-anxiety and/or HADS-depression before the outbreak was associated 
with worsening of exercise during the outbreak (OR 1.38, 95%CI 1.03-1.86). A higher webEDSS 
score among pwMS was not significantly associated with worsening of exercise (OR 1.03, 95%CI 
0.96-1.11), but predicted a lower likelihood of having better exercise during the outbreak than before 
(OR 0.77, 95%CI 0.71-0.84) (n=1,541; adjusted for age, gender, taking DMTs, and MS type). 
Controls were more likely to have improved their diet than pwMS during the outbreak (1.64, 95%CI 
1.16-2.32). 
PwMS were not significantly different from controls in terms of having undergone a change in their 
work (OR 0.80, 95%CI 0.59-1.08). A higher webEDSS score predicted a lower likelihood of 
undergoing a change in work among pwMS (OR 0.86, 95%CI 0.80-0.92) (n=1,541; adjusted for age, 
gender, MS type, and taking DMTs). Among participants whose work had changed, pwMS were more 
likely to report being more stressed by this change than controls (OR 2.40, 95%CI 1.12-5.18). PwMS 
with and without anxiety and/or depression during the outbreak were not significantly different in 
feeling more stressed due to a change in work (OR 1.29, 95%CI 0.64-2.60). The absence of anxiety 
and depression among pwMS, however, was associated with a higher likelihood of feeling less 
stressed due to a change in work (OR 3.64, 95%CI 1.95-6.80) (n=347; adjusted for changes in 
support, relationships, and income). 
Compared to controls, pwMS were more likely to experience a reduction in their income during the 
outbreak (OR 1.41, 95%CI 1.04-1.90). Among participants who underwent a change in work, there 
was no significant difference between pwMS and controls in having a reduction (OR 1.09, 95%CI 
0.63-1.88) or increase in income (OR 0.89, 95%CI 0.39-2.06).  
DISCUSSION  
Our findings add to the evidence that pwMS are more likely to experience anxiety and depression 
than the general population.4, 5 This study on a large national population of pwMS covers the first 
lockdown in the UK, which started on 23 March 2020 and was eased on 4 July 2020. We did not find 
a significant change in the levels of anxiety and depression among pwMS during this period compared 
to the year before, which is consistent with the results of other studies.20-22 Taken together, these 
findings suggest that the differences we, and others,22, 23 have found in anxiety and depression 
between pwMS and those without MS during the outbreak were most likely due to MS-related factors 
rather than the outbreak at the early phases of the pandemic. Studies of the general population have 
shown that levels of psychological distress have increased during the pandemic and people with 
higher risk of COVID-19, young adults, women, and populations with pre-existing mental or physical 
health conditions have fared even worse.2, 24 Given that pwMS meet one or more of these conditions, 
we have considered why their anxiety and depression levels have not changed in line with general 
population surveys. One reason could be because pwMS are resilient,20 or because support systems 
were already in place for pwMS and these were agilely mobilised to address the concerns of this 
population quickly when the pandemic started (e.g., the local branches of the UK MS Society, which 
has peer-support groups and had a helpline that was available for pwMS);25 more than 85% of pwMS 
in our study reported that the social support they received before the outbreak had improved or had 
not changed during the outbreak. We do not know whether the pandemic will have a more profound 
effect on pwMS in the future. Studies should continue to monitor the mental wellbeing of pwMS 
throughout the pandemic and thereafter. 
Poor mental health has a negative impact on the quality of life, and physical and cognitive function of 
pwMS.26 The study found that anxiety and depression have a substantial negative effect on the general 
health of pwMS and their MS symptoms, which can be greater than the impact of COVID-19. This 
points to a need for MS services to provide continued targeted multidisciplinary psychological support 
for this population. 
We found that many pwMS were feeling lonelier during the outbreak than before and they were more 
likely to feel this way if they had anxiety or depression. PwMS were slightly more likely than people 
without MS to feel lonelier during the outbreak. The observations that loneliness is linked with poor 
health-related outcomes and depression,27-29 along with our findings, point to a need to address 
loneliness among pwMS during periods of lockdown. Interventions for homebound older adults, that 
improve social connectedness and reduce depressive symptoms and disability,30 could be adapted for 
pwMS. 
Many pwMS did not experience any changes in their social support, relationships, work, or income 
after the outbreak, suggesting that the response of the MS community to the unforeseen 
transformations at the early stages of the pandemic was effective. The lockdown also had potential 
benefits to pwMS which have been pointed out by other authors.20 However, when there was a change 
in these social factors, pwMS were affected more adversely than those without MS. 
The restrictions imposed by the pandemic limited the physical activity of pwMS and did not provide 
them the opportunity to develop better diets compared to people without MS. Therefore, pwMS 
appear to be more susceptible to the adverse effects of the outbreak on lifestyle. These are important 
aspects for clinicians to assess and address in routine encounters because improving lifestyle factors 
(such as exercise) can improve the mental and physical health of pwMS.31, 32 
Our results confirm that anxiety and depression in pwMS are not specific to the COVID-19 era: they 
have remained high before and during the pandemic. Social and lifestyle factors have an undeniable 
role in mental health,5-8 but these factors changed in different directions among our study population 
of pwMS (for example, some felt lonelier while others received better social support during the 
outbreak) which could have resulted in the stable anxiety and depression levels observed among 
pwMS.  
It is not uncommon for mental health conditions to go undetected.33 There is scope for effective 
management of anxiety and depression in pwMS, and modifications in lifestyle and social factors may 
provide additional benefits to their health-related quality of life.34, 35 Therefore, it is vital that 
clinicians routinely screen for mental health problems, particularly in this COVID-19 era, and refer 
pwMS to appropriate wellbeing or mental health services for further assessment and support. It is also 
important that the MS community is aware of their specific vulnerabilities, so that they can take steps 
to proactively seek support. 
Limitations of the study 
We cannot precisely calculate our response rate (in pwMS and controls) as we do not know how many 
people received the study emails. This is a common limitation in studies that recruit participants 
through registries or social media.24 We tried to increase our recruitment by advertising the study and 
sending reminder emails.36 Nevertheless, we have studied a large national population of pwMS- the 
largest among current COVID-19 and mental health studies among pwMS. 
The mental health study MS sample had slightly lower levels of anxiety than non-participants from 
the UKMSR and, therefore, their response to the pandemic could have been different. Nevertheless, 
our findings are in keeping with the results of similar studies.20-22 
Different cut-offs have been recommended to identify caseness of anxiety and depression using 
HADS.37 Here, we used a priori cut-off based on a validation study in MS.13 
Failure to find a difference between HADS scores before and during the outbreak might be influenced 
by seasonal effects on experiencing anxiety and depression symptoms. Changes in HADS score could 
not be tested for each season in 2019 and 2020 separately because of small sample sizes. 
The UKMSR was not collecting data on social and lifestyle determinants of mental health (as assessed 
in this study) before the COVID-19 outbreak. Therefore, we were unable to directly compare these 
factors during and before the outbreak. We tried to overcome this problem by asking participants 
about changes in these factors during the COVID-19 outbreak compared to before. 
We asked pwMS to invite people without MS (“controls”) to the study who could be their friends and 
relatives, sharing similar social networks or living in similar neighbourhoods with similar 
socioeconomic status. This can be a strength in that the controls and pwMS are similar but could also 
lessen the actual difference between their mental health status. However, the proportion of controls 
who had anxiety and/or depression in our study (27.1%) is comparable to findings among the UK 
general population during the same period (27.3%).2 
We included self-reported COVID-19 instead of confirmed cases since the sample size for the latter 
was small. However, pwMS with anxiety and/or depression did not tend to report having had COVID-
19 any more than pwMS without anxiety or depression. 
We could not study the association between ethnicity and mental health because the number of people 
from ethnic backgrounds other than White ethnicity in the UKMSR was small.  
Acknowledgements 
We would like to thank the participants of the UKMSR and those who took part in the COVID-19 
study. We would also like to thank all MS teams that have encouraged and supported people with MS 
throughout the pandemic at National Health Service (NHS) sites across the UK. Richard Morriss 
would like to acknowledge his funding from the National Institute of Health Research (NIHR) 
Applied Research Collaboration East Midlands, the NIHR Mind Tech Medical Technology and In-
vitro Centre, the Nottingham NIHR Biomedical Research Centre, and a NIHR Senior Investigator 
Award to support his time. 
Declaration of Conflicting Interests 
All authors have completed the Unified Competing Interest Form which is available on request from 
the corresponding author. 
AG has received a grant from the UK MS society as part of the UK MS Register. 
RH: none declared. 
GRL: none declared. 
RMM has received a grant from the UK MS society as part of the UK MS Register. 
KTD has received a grant from the UK MS society as part of the UK MS Register. 
RD has received speaker honoraria from Biogen Idec, Teva, Neurology Academy, and Sanofi 
Genzyme. She has received research support from Biogen, Merck, and Celgene. 
DVF has received a grant from the UK MS society as part of the UK MS Register. 
SH has received unrestricted educational grants or speaking honoraria from Biogen, Merck Serono, 
Novartis, Roche and Sanofi-Aventis. 
ORP has received honoraria and travel expenses from Biogen, Bayer, Genzyme, Merck, Novartis, 
Roche, and Teva. He has served on advisory boards for Biogen, Celgene, Novartis, Genzyme, Merck, 
and Roche. 
DR has received consulting fees from Bayer, Celgene, Biogen, Janssen-Cilag, MedDay, Merck 
Serono, Novartis, Roche, Sanofi Genzyme, and Teva Neuroscience. He has received research support 
from Actelion, Biogen, GW Pharma, Janssen-Cilag, MedDay, Merck Serono, Mitsubishi, Novartis, 
Sanofi Genzyme, Teva Neuroscience, and TG Therapeutics. 
ECT has received consulting or speaker fees from Roche, Novartis, and Takeda and travel expenses to 
attend educational meetings from Biogen, Merck, and Roche. 
RN has received support for advisory boards and travel from Novartis, Roche, and Biogen. He has 
received grant support from the MS Society. He is a member of a NICE HTA committee. 
RM: none declared. 
NE is a member of the advisory board for Biogen, Merck, Novartis, and Roche. He has received grant 
income from the MS Society, MRC, PCORI and NIHR. 
RdN is the Chair of the NIHR Research for Patient Benefit East Midlands Research Advisory 
Committee. He has received funding to prepare and deliver lectures on cognitive rehabilitation in 
multiple sclerosis from Novartis and Biogen. 
Funding 
The authors disclosed receipt of the following financial support for the research, authorship, and/or 
publication of this article: This work was supported by the United Kingdom Multiple Sclerosis 
Society [grant number 131]. 
Authors contributions 
RdN, RH, NE, and RN conceived the idea of the study. RdN, RH, AG, RMM, KTD, NE, and RN 
were involved in the design and execution of the study including data collection. Data were collected 
through the UK MS Register with support from RMM, KTD, and DVF. AG carried out pooling of the 
data with support from RMM. AG performed the data analysis with support from GRL. The 
manuscript was drafted by AG and RdN, revised by RM, RH, NE, RN, and GRL, with intellectual 
contributions from all authors.  
References 
1. Pfefferbaum B and North CS. Mental health and the Covid-19 pandemic. New England 
Journal of Medicine 2020; 383: 510-512. 
2. Pierce M, Hope H, Ford T, et al. Mental health before and during the COVID-19 pandemic: a 
longitudinal probability sample survey of the UK population. The Lancet Psychiatry 2020; 7: 883-
892. 
3. Holmes EA, O'Connor RC, Perry VH, et al. Multidisciplinary research priorities for the 
COVID-19 pandemic: a call for action for mental health science. The Lancet Psychiatry 2020. 
4. Marrie RA, Walld R, Bolton JM, et al. Estimating annual prevalence of depression and 
anxiety disorder in multiple sclerosis using administrative data. BMC research notes 2017; 10: 1-6. 
5. Boeschoten RE, Braamse AM, Beekman AT, et al. Prevalence of depression and anxiety in 
multiple sclerosis: a systematic review and meta-analysis. Journal of the neurological sciences 2017; 
372: 331-341. 
6. Brown RF, Valpiani EM, Tennant CC, et al. Longitudinal assessment of anxiety, depression, 
and fatigue in people with multiple sclerosis. Psychology and Psychotherapy: Theory, Research and 
Practice 2009; 82: 41-56. 
7. Henry A, Tourbah A, Camus G, et al. Anxiety and depression in patients with multiple 
sclerosis: The mediating effects of perceived social support. Multiple sclerosis and related disorders 
2019; 27: 46-51. 
8. Ratajska A, Glanz BI, Chitnis T, et al. Social support in multiple sclerosis: Associations with 
quality of life, depression, and anxiety. Journal of Psychosomatic Research 2020; 138: 110252. 
9. Evangelou N, Garjani A, dasNair R, et al. Self-diagnosed COVID-19 in people with multiple 
sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery 
&amp; Psychiatry 2020: jnnp-2020-324449. DOI: 10.1136/jnnp-2020-324449. 
10. Middleton R, Rodgers W, Chataway J, et al. Validating the portal population of the United 
Kingdom multiple sclerosis register. Multiple sclerosis and related disorders 2018; 24: 3-10. 
11. Leddy S, Hadavi S, McCarren A, et al. Validating a novel web-based method to capture 
disease progression outcomes in multiple sclerosis. Journal of neurology 2013; 260: 2505-2510. 
12. Zigmond AS and Snaith RP. The hospital anxiety and depression scale. Acta psychiatrica 
scandinavica 1983; 67: 361-370. 
13. Marrie RA, Zhang L, Lix LM, et al. The validity and reliability of screening measures for 
depression and anxiety disorders in multiple sclerosis. Multiple sclerosis and related disorders 2018; 
20: 9-15. 
14. Kroenke K, Spitzer RL and Williams JB. The PHQ‐9: validity of a brief depression severity 
measure. Journal of general internal medicine 2001; 16: 606-613. 
15. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety 
disorder: the GAD-7. Archives of internal medicine 2006; 166: 1092-1097. 
16. Weiss DS. The impact of event scale: revised. Cross-cultural assessment of psychological 
trauma and PTSD. Springer, 2007, pp.219-238. 
17. Scheier MF, Carver CS and Bridges MW. Distinguishing optimism from neuroticism (and 
trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. Journal of 
personality and social psychology 1994; 67: 1063. 
18. Greenland S, Pearl J and Robins JM. Causal diagrams for epidemiologic research. 
Epidemiology 1999: 37-48. 
19. Rohrer JM. Thinking clearly about correlations and causation: Graphical causal models for 
observational data. Advances in Methods and Practices in Psychological Science 2018; 1: 27-42. 
20. Capuano R, Altieri M, Bisecco A, et al. Psychological consequences of COVID-19 pandemic 
in Italian MS patients: signs of resilience? Journal of neurology 2020: 1-8. 
21. Chiaravalloti ND, Amato MP, Brichetto G, et al. The emotional impact of the COVID-19 
pandemic on individuals with progressive multiple sclerosis. Journal of Neurology 2020: 1-10. 
22. Stojanov A, Malobabic M, Milosevic V, et al. Psychological status of patients with relapsing-
remitting multiple sclerosis during coronavirus disease-2019 outbreak. Multiple Sclerosis and Related 
Disorders 2020; 45: 102407. 
23. Motolese F, Rossi M, Albergo G, et al. The Psychological Impact of COVID-19 Pandemic on 
People With Multiple Sclerosis. Frontiers in neurology 2020; 11: 1255. 
24. Jia R, Ayling K, Chalder T, et al. Mental health in the UK during the COVID-19 pandemic: 
cross-sectional analyses from a community cohort study. BMJ open 2020; 10: e040620. 
25. MS Society. Keeping our MS community safe, https://www.mssociety.org.uk/what-we-
do/keeping-safe-during-the-coronavirus-covid-19-outbreak (accessed 16 April 2021). 
26. Battalio SL, Glette M, Alschuler KN, et al. Anxiety, depression, and function in individuals 
with chronic physical conditions: A longitudinal analysis. Rehabilitation Psychology 2018; 63: 532. 
27. Cacioppo JT, Hawkley LC and Thisted RA. Perceived social isolation makes me sad: 5-year 
cross-lagged analyses of loneliness and depressive symptomatology in the Chicago Health, Aging, 
and Social Relations Study. Psychology and aging 2010; 25: 453. 
28. Theeke LA. Sociodemographic and health-related risks for loneliness and outcome 
differences by loneliness status in a sample of US older adults. Research in Gerontological Nursing 
2010; 3: 113-125. 
29. Mullen RA, Tong S, Sabo RT, et al. Loneliness in primary care patients: a prevalence study. 
The Annals of Family Medicine 2019; 17: 108-115. 
30. Choi NG, Pepin R, Marti CN, et al. Improving social connectedness for homebound older 
adults: randomized controlled trial of tele-delivered behavioral activation versus tele-delivered 
friendly visits. The American Journal of Geriatric Psychiatry 2020; 28: 698-708. 
31. Ensari I, Motl RW and Pilutti LA. Exercise training improves depressive symptoms in people 
with multiple sclerosis: results of a meta-analysis. Journal of psychosomatic research 2014; 76: 465-
471. 
32. Pilutti LA, Greenlee TA, Motl RW, et al. Effects of exercise training on fatigue in multiple 
sclerosis: a meta-analysis. Psychosomatic medicine 2013; 75: 575-580. 
33. Cepoiu M, McCusker J, Cole MG, et al. Recognition of depression by non-psychiatric 
physicians—a systematic literature review and meta-analysis. Journal of general internal medicine 
2008; 23: 25-36. 
34. Sarris J, O’Neil A, Coulson CE, et al. Lifestyle medicine for depression. BMC psychiatry 
2014; 14: 1-13. 
35. Kidd T, Carey N, Mold F, et al. A systematic review of the effectiveness of self-management 
interventions in people with multiple sclerosis at improving depression, anxiety and quality of life. 
PloS one 2017; 12: e0185931. 
36. MS Society. Help us understand more about COVID-19 and MS, 
https://www.mssociety.org.uk/research/latest-research/latest-research-news-and-blogs/help-us-
understand-more-about-covid-19-and-ms (2020, accessed 11 January 2021). 
37. Olssøn I, Mykletun A and Dahl AA. The Hospital Anxiety and Depression Rating Scale: a 
cross-sectional study of psychometrics and case finding abilities in general practice. BMC psychiatry 
2005; 5: 1-7. 
 
